Poinsettia announced on December 14 that US Arthrosi Therapeutics, Inc. in which the company is a shareholder has received the relevant terms of the agreement issued by Sobi US. Sobi US plans to acquire 100% of Arthrosi's shares with a down payment of 950 million US dollars and clinical, registration and sales milestone payments of up to 550 million US dollars. The company holds 13.45% of Arthrosi's shares through its wholly-owned subsidiary Ruiteng Biotech Co., Ltd.

Zhitongcaijing · 2d ago
Poinsettia announced on December 14 that US Arthrosi Therapeutics, Inc. in which the company is a shareholder has received the relevant terms of the agreement issued by Sobi US. Sobi US plans to acquire 100% of Arthrosi's shares with a down payment of 950 million US dollars and clinical, registration and sales milestone payments of up to 550 million US dollars. The company holds 13.45% of Arthrosi's shares through its wholly-owned subsidiary Ruiteng Biotech Co., Ltd.